Novo Nordisk's Keenly Awaited Semaglutide Trial To ‘Redefine’ Alzheimer’s?

Late-Stage EVOKE Set To Complete September 2025

 
• By Sten Stovall
  
Semaglutide trial to assess GLP-1 impact on neuro-inflammation • Source: Alamy
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from R&D